Page last updated: 2024-08-23

raloxifene hydrochloride and Bone Cancer

raloxifene hydrochloride has been researched along with Bone Cancer in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jordan, VC	1
Cremers, S; Garnero, P	1
Namazi, H	1
Boersma, CJ; Dijkema, R; Mosselman, S; Mulder, WR; Olijve, W; van den Wijngaard, A; van Zoelen, EJ	1

Reviews

1 review(s) available for raloxifene hydrochloride and Bone Cancer

Article	Year
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs, 2006, Volume: 66, Issue:16 Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Remodeling; Bone Resorption; Calcitonin; Cathepsin K; Cathepsins; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Female; Humans; Organometallic Compounds; Osteitis Deformans; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Thiophenes	2006

Article

Year

Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

Drugs, 2006, Volume: 66, Issue:16

Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Remodeling; Bone Resorption; Calcitonin; Cathepsin K; Cathepsins; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Female; Humans; Organometallic Compounds; Osteitis Deformans; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Thiophenes

2006

Other Studies

3 other study(ies) available for raloxifene hydrochloride and Bone Cancer

Article	Year
A STAR is born. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:9 Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2006
Raloxifene can reduce giant cell tumor recurrence: a new adjuvant therapy. Annals of surgical oncology, 2008, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Bone Neoplasms; Giant Cell Tumors; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride	2008
Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. Molecular endocrinology (Baltimore, Md.), 2000, Volume: 14, Issue:5 Topics: Adenocarcinoma; Base Sequence; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Breast Neoplasms; Cells, Cultured; Dimerization; Drug Design; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation; Humans; Molecular Sequence Data; Neoplasms, Hormone-Dependent; Organ Specificity; Osteoblasts; Osteogenesis; Osteoporosis; Osteosarcoma; Postmenopause; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Stimulation, Chemical; Transfection; Tumor Cells, Cultured	2000